Nalaganje...
Phase II Trial of Weekly Ixabepilone in Men With Metastatic Castrate-Resistant Prostate Cancer (E3803): A Trial of the Eastern Cooperative Oncology Group
Ixabepilone is an epothilone B analogue with activity in a variety of solid malignancies, including prostate cancer. The main dose-limiting toxicity of ixabepilone is myelosuppression when administered by using an every 3-week schedule. Here we evaluate the activity of a weekly ixabepilone in men wi...
Shranjeno v:
| Main Authors: | , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2012
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3535436/ https://ncbi.nlm.nih.gov/pubmed/22386239 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2012.01.009 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|